Proceed with caution, this is not financial advice. I merely intend to inform you of my observations and of my personal position. I am of course biased as I have already chosen to invest, but I feel bad not letting others in on this lesser known stock with very bullish outlooks.
I recognize bullish indicators in my Stoch RSI and in candle analysis. Also, the...
Revolve has had a rocky time since its IPO, with lots of volatility and several breaks below critical trend lines. However, this company is profitable, undervalued, and highly rated, and in my opinion it's still a great value.
With Revolve having breached the bottom of its parallel channel today, it's likely to establish a new channel. I've drawn a couple...
Today looks like a good entry on RVLV, with the price testing the bottom of its parallel channel. RVLV also has a volume support node at 35.27 and is close to oversold on the RSI. We just got an upward stochastic cross as well.
RVLV is undervalued and has bullish analyst ratings.
Another of the IPO's I really like this year is CRWD, they will report earnings for the first time this Thursday.
Most analysts have a buy rating, with a price target 90$-100$. Meaning 12.5%-25% potential upside.
Stitch Fix is at support from a high-volume node on the volume profile and from its 50-day moving average. It also has some RSI support around 38.
The stock just got some big analyst upgrades from Zacks and Goldman, which could serve as upside catalysts. The Internet retail sector is currently outperforming the S&P 500. S&P Capital IQ rates Stitch Fix as...
One of this year's hottest IPOs is still winning over new fans. Dmitry Netis at Stephens is initiating coverage of Zoom Video (ZM) with a bullish overweight rating.
The analyst's price target of $115 suggests that there's 26% of upside from current levels, an encouraging goal for the provider of video-conferencing solutions for enterprises that has already...
Something I came across that normally would result in the suggested move...
Selling $175 with a move towards the previous pivot LO with possible continuation towards a gap close.
This would capture a nice 15%+ move.
"Microsoft and Adaptive Biotechnologies announce partnership using AI to decode immune system; diagnose, treat disease"
They also have a partnership with Genentech (January 2019)
ADPT - Adaptive Biotechnology
IPO: June 27th 2019 - open @$39 (above current price)
Vision: We aim to improve people’s lives by translating the scale and precision of their adaptive...
Akerna coming into that buy zone. Stock IPOed (actually it was a SPAC) at around $11 after doing their last private placement at $10.21. As this is a recent IPO (of sorts) and a cannabis company, I expect this will eventually shake out at 2x the IPO price (around $20) so buy on dips.
Why 2x IPO price? Look at high flyers Zoom $ZM, Beyond Meat $BYND,...
This was the hottest IPO of 2019. Statistically it was totally out of the line with others. But it happened and I'm glad that I was in it
The company is fine and the product is great.
But the revenue and the growth pace need to find balance with the market value of the company.
As soon as greed ends and we move to lock up period end BYND should correct...
Look to buy at support of 36.26, with current stop loss of 36.06. Move that stop loss up periodically to keep it just below the channel.
This is just an idea as to how the market will move, not investment advice.